URGENT UPDATE: A major new review reveals that millions of people taking antidepressants face heightened risks of weight gain, hypertension, and serious heart problems. Researchers at King’s College London analyzed data from 58,500 patients across 30 different antidepressants and found alarming differences in cardiovascular side effects.
Published in The Lancet, the study highlights that amitriptyline, one of the most frequently prescribed tricyclic antidepressants, resulted in weight gain for nearly half of users. Patients experienced an average 9 bpm rise in heart rate and a 5 mmHg increase in systolic blood pressure after just eight weeks. These changes elevate the risk of stroke by 5 percent and overall mortality by nearly 10 percent.
“Antidepressants are among the most widely used medicines in the world. While many people benefit from them, some can lead to meaningful changes in weight, heart rate, and blood pressure in a relatively short period,” stated Dr. Toby Pillinger, the study’s senior author.
Other medications like nortriptyline showed an increase in heart rate by 13 bpm, while mirtazapine was associated with significant weight gain. In a contrasting finding, patients using citalopram, a common SSRI, actually lost an average of 0.65 kg and demonstrated slight improvements in blood pressure and heart rate.
This urgent study underscores the critical need for routine health checks for those on long-term antidepressants, especially with 8.8 million people currently taking these medications in England. Experts warn that the actual risks may be “much higher,” as many patients remain on these drugs for extended periods.
Dr. Prada Nishtala from the University of Bath cautioned against underestimating the potential side effects. While experts stress that individuals should not discontinue their medication without consulting a healthcare provider, the authors advocate for “shared decision-making” in prescriptions and increased awareness of physical side effects.
“All known side effects are clearly outlined in medicine leaflets,” reassured Dr. Alison Cave, chief safety officer at the MHRA. “We encourage anyone with concerns to consult their doctor or report symptoms via the Yellow Card scheme.”
As more patients seek mental health support, the implications of this research are profound. It is crucial for patients and healthcare providers to engage in open discussions regarding the benefits and risks of antidepressant medications, especially in light of these significant findings.
Stay tuned for further updates on this developing story and the broader implications for mental health treatment across the globe.
